Forest etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Forest etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

21 Eylül 2016 Çarşamba

Indonesia dismisses study showing forest fire haze killed more than 100,000 people

Indonesian, Malaysian and Singaporean authorities have dismissed research that suggested smoky haze from catastrophic forest fires in Indonesia last year caused 100,000 deaths. Some even contend the haze caused no serious health problems, but experts say those assertions contradict well-established science.


Last year’s fires in Sumatra and the Indonesian part of Borneo were the worst since 1997, burning about 261,000 hectares of forests and peatland and sending haze across the region for weeks. Many were deliberately set by companies to clear land for palm oil and pulpwood plantations.


The study in the journal Environmental Research Letters by Harvard and Columbia researchers estimated the amount of health-threatening fine particles, often referred to as PM2.5, released by the fires that burned from July to October and tracked their spread across south-east Asia using satellite observations.


In Indonesia, a spokesman for the country’s disaster mitigation agency said the research “could be baseless or they have the wrong information”. Indonesia officially counted 24 deaths from the haze including people killed fighting the fires.


Singapore’s Ministry of Health said short-term exposure to haze will generally not cause serious health problems. The study was “not reflective of the actual situation”, it said, and the overall death rate hadn’t changed last year.


In Malaysia, health minister Subramaniam Sathasivam said officials are still studying the research, which is “computer-generated, not based on hard data”. “People have died but to what extent the haze contributed to it, it’s hard to say,” he said. “If an 80-year-old fellow with high blood pressure, diabetes, heart problem and exposure to haze died, what did he die of? This is a hell of a difficult question to answer.”


The dry season fires are an annual irritant in Indonesia’s relations with its neighbours Singapore and Malaysia and the finding of a huge public health burden has the potential to worsen those strains. The 2015 burning season, which was worsened by El Niño’s dry conditions, also tainted Indonesia’s reputation globally by releasing a vast amount of atmosphere-warming carbon.


The Indonesian government has stepped up efforts to prosecute companies and individuals who set fires and also strengthened its fire-fighting response. This year’s fires have affected a smaller area in large part due to unseasonal rains.


Jamal Hisham Hashim, research fellow with the International Institute for Global Health in Kuala Lumpur, Malaysia, said governments should not dismiss the study even if the estimated deaths are arguable.


He said decades of air pollution research that followed London’s killer smog in 1952 has established the relationship between fine particulate matter and premature deaths, particularly in people with existing respiratory and cardiovascular diseases.


“The pollution level that occurred during the haze is severe enough to cause premature deaths. That is indisputable,” he said. “The study is a wake-up call. We need to be shaken; we have become too complacent with the haze.”


Joel Schwartz, an author of the study who is regarded by his peers as one of the world’s top experts on the health effects of air pollution, said authorities in the affected countries have not offered any details of how they reached conclusions critical of the study.


During the haze, Malaysia suffered air pollution at 10 times the level that the World Health Organization says causes premature deaths, he said, while Singapore’s claim that short-term exposure does not have serious effects is factually incorrect.
The Singaporean statement that its death rate was unchanged from 2014 did not demonstrate anything, Schwartz said, due to a worldwide trend for declining mortality. The study’s premise is that deaths are higher than what they would be without the haze rather than a comparison to a particular year, he said.


Separately, Singapore’s health ministry did not respond to a question on why heart disease and pneumonia, both of which can be brought to fatal conclusion by fine particle exposure, had increased as a percentage of deaths in 2015.


Malaysia, meanwhile, does not measure PM2.5 in its air pollution index but has been planning to from next year.


Half a dozen scientists with expertise in air pollution who reviewed the study for the Associated Press said its methodology was sound and its conclusions reasonable. Some cautioned that the estimates of 91,600 deaths in Indonesia, another 6,500 in Malaysia and 2,200 in Singapore are invariably uncertain because aspects of the modelling rely on assumptions and the actual figures could be higher or lower.


The study considered only the health impact on adults and restricts itself to the effects of fine particles rather than all toxins that would be in the smoke.


Philip Hopke, director of the Center for Air Resources Engineering and Science at New York state’s Clarkson University, said air pollution studies have to overcome several challenges because “no one who gets sick or dies comes to the doctor or hospital with a clear label that says airborne particles or ozone did this.” Another problem is the studies typically assume that fine particles are the sole cause of illness or death but smoke from fires contains ozone and a variety of volatile compounds that would also affect health.


“A major event like occurred here is extremely likely to have caused adverse health outcomes in terms of both sickness and deaths,” he said.



Indonesia dismisses study showing forest fire haze killed more than 100,000 people

18 Şubat 2014 Salı

Massive Deal: $25 Billion Forest Sale Cements A Turnaround Artist"s Reputation

There’s a stream of internet jokes from a few years back that lauded the mythical – and impossible – achievements of martial arts star Chuck Norris. “Chuck Norris can cut via a sizzling knife with butter,” one particular mentioned. “Chuck Norris counted to infinity – twice. Chuck Norris is the reason Waldo is hiding.”


Huge pharma M&ampA just got its Chuck Norris.


I’m commencing to wonder if you could give Brent Saunders, who has now rebuilt and sold off two legendary health care brand names, just about any distressed drug firm and see it purchased a quick time later for a big, juicy premium. Practically 5 many years in the past, he took more than eye care business Bausch &amp Lomb, which had been taken personal soon after some of its goods led to deadly eye infections. “By the time we offered the business to Valiant three and a half many years later, B&ampL had the best late-stage pipeline it had ever had in its 160 many years at that point,” Saunders stated at the Forbes Healthcare Summit last 12 months. Valeant paid $ 9 billion.


Now the larger fish: 9 months ago Saunders took in excess of Forest Laboratories, the legendary drug organization that, beneath chief executive Howard Solomon in the 1990s, had pioneered a new organization model. Instead of inventing its very own medicines, Forest purchased medicines that had been laying fallow someplace else. Inspired by his son’s struggles with depression, Solomon launched two of the hottest antidepressants ever, Celexa and Lexapro, and manufactured Forest into one of the industry’s electrical power players.


Also on Forbes: When It is Time To Sell Your Organization


But patents on these drugs expired, and the patent on Namenda, a blockbuster Alzheimer’s condition therapy, would go soon. In an extra insult, U.S. officials even threatened to ban Solomon from selling to Medicare and Medicaid in connection with false claims act allegations, including that Forest had pushed Celexa on children. Carl Icahn had taken a stake in the business, and was pushing for new management.


Saunders, currently a Forest board member, took the reins and quickly received Wall Street fired up again. Saunders purchased the rights to Saphris, an antipsychotic that Saunders knew from his time at Schering-Plough, from Merck Merck for $ 240 million. He worked to create successors to Namenda, which includes a delayed release version, to sustain market share.  And he spent $ two.9 billion to get Aptalis, which tends to make drugs to ease the digestive troubles connected to cystic fibrosis and would add $ 700 million in income.


In a note to investors on January 31, Leerink pharmaceutical analyst Seamus Fernandez praised Saunders’ “tireless enthusiasm for the sector and prospects for [Forest],” crowing that an early closure of the Aptalis deal could add 5 or ten cents per share to earnings for 2014 and advised investors to buy the stock. Vamil Divan at Credit Suisse, was equally bullish, telling consumers that Forest was “in the early innings of a multi-12 months rejuvenation story.” On February four, Chris Schott, the pharmaceuticals analyst at J.P. Morgan J.P. Morgan, initiated coverage on the stock with a acquire rating, pointing in portion to Saunders’ experience at Bausch &amp Lomb and his capacity to leverage money flow to pursue much more acquistions.


This morning, Forest announced that it is getting bought by generic drug maker Aptavis for $ 25 billion. The supply involves $ 26.04 in funds and .3306 Actavis Actavis shares for every share of Forest that functions out to $ 89.48 per share for the organization, or a 105% return for traders who purchased the stock when Saunders was named as CEO on September 10 of final 12 months.


“I venture to say that as a CEO you really don’t target on promoting the organization, even if you’re personal and that’s portion of what you want to do,” Saunders said at the Forbes summit back in December. “You target on developing the strongest, ideal organization you can and if some thing comes out of left field, or by way of a method, or whatever it might be, that is the correct factor for your shareholders than you do it.”


This time it only took 9 months. Analysts who cover Forest are – huge surprise – saying that the deal need to make fiscal sense for Actavis. I believe that investors need to want to kick the tires a bit on that. Just as Chuck Norris didn’t actually do any of individuals cool issues at the best of the story, there’s a bit of myth-making concerned in firm turnarounds. Bausch really did require a great deal of work, and Saunders essential to obtain and launch merchandise. The turnaround and Forest has been more quickly and much more subtle, and it is worth pondering if swings in investor sentiment have as considerably to do with the buy price as changes in the company’s fundamental enterprise. AstraZeneca is rumored to have entertained a $ 15 billion bid surely that would have been a far better deal from the buyer’s viewpoint, even without having Saunders’ handiwork?


But the actuality is that most turnarounds are a bit of a psychological trick. That was correct, also, for Saunders’ mentor, Fred Hassan, who turned close to Pharmacia and Schering-Plough. You really do not hear doubts about Inspra, the supposed blockbuster heart drug Pfizer received with Pharmacia that then fizzled, or queries about vorapaxar, Schering’s supposedly fantastic blood thinner, attached to him a lot these days. People bear in mind the offers. And the very same will be true here.


Wall Street will bear in mind the tremendous returns Saunders delivered. That’s why he will not be out of the CEO seat for very long – and why, when he pops up once again, you must take into account acquiring the stock.


Adhere to me on Twitter @matthewherper.


Also on Forbes: Anatomy Of A Turnaround


 



Massive Deal: $25 Billion Forest Sale Cements A Turnaround Artist"s Reputation